Hypermarcas S.A. Business Summary

Hypera S.A. (HYPMY), formerly Hypermarcas, operates as Brazil’s largest pharmaceutical company by market capitalization, generating revenue through the large-scale manufacturing and commercialization of healthcare products. Its business model is diversified across five primary segments: Consumer Health, which leads the Brazilian market with iconic over-the-counter (OTC) brands like Benegrip, Buscopan, and Neosaldina; Branded Prescription, anchored by the Mantecorp Farmasa umbrella; Similars and Generics, operated through the Neo Química brand; Skincare, featuring Mantecorp Skincare and Simple Organic; and a growing Non-Retail division serving hospitals and clinics. The company leverages the largest pharmaceutical industrial complex in Latin America, located in Anápolis, to maintain a low-cost, high-efficiency production cycle. Hypera competes directly with domestic giants such as EMS, Eurofarma, and Aché, as well as multinational players like Sanofi and Abbott, maintaining its edge through a dominant 17% market share in key retail segments and an extensive national distribution network. The company was founded by João Alves de Queiroz Filho (known as Júnior), who remains a pivotal figure and major shareholder with a 27.3% stake as of February 2026. The current leadership team is headed by CEO Breno Toledo Pires de Oliveira, who transitioned from the CFO role in 2018 to lead the company’s pharmaceutical-centric pivot. Financial operations are overseen by CFO and Investor Relations Officer Ramon Sanches Frutuoso Silva, while Tiago Feltrin serves as the Director of Technology & Digital (CTO equivalent). The Board of Directors is chaired by Álvaro Stainfeld Link, a former Goldman Sachs executive, and includes notable members such as Cláudio Ermírio de Moraes, representing the Votorantim Group. Key institutional backing is provided by the Votorantim Group and the Mexican holding company Maiorem, which together with the founder form a controlling block that recently reinforced the company’s independence by committing to a R$1.5 billion capital increase in early 2026.